TrialJournal of the European Academy of Dermatology and Venereology : JEADV2021

First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.

M Kaul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.